(NASDAQ: VCEL) Vericel's forecast annual revenue growth rate of 17.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 105.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.71%.
Vericel's revenue in 2025 is $258,717,000.On average, 10 Wall Street analysts forecast VCEL's revenue for 2025 to be $14,199,163,540, with the lowest VCEL revenue forecast at $13,555,356,189, and the highest VCEL revenue forecast at $14,664,950,319. On average, 10 Wall Street analysts forecast VCEL's revenue for 2026 to be $17,360,040,165, with the lowest VCEL revenue forecast at $15,909,577,099, and the highest VCEL revenue forecast at $18,615,793,230.
In 2027, VCEL is forecast to generate $21,248,171,284 in revenue, with the lowest revenue forecast at $18,427,152,113 and the highest revenue forecast at $23,388,969,804.